One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
2021 Presidential Address: Equity: Every Patient. Every Day. Everywhere
Pierce, Lori J. MD; FASTRO, FASCO1,2,,
doi : 10.1200/JCO.21.01418
Volume 39(23), 10 August 2021, p 2521-2524
Improving Outcomes in Children With High-Risk Neuroblastoma: The Role of Randomized Trials
DuBois, Steven G. MD1,; Bagatell, Rochelle MD2,
doi : 10.1200/JCO.21.01066
Volume 39(23), 10 August 2021, p 2525-2527
Management of Women With Breast Cancer and Pathogenic Variants in Genes Other Than BRCA1 or BRCA2
Robson, Mark MD1,,
doi : 10.1200/JCO.21.00999
Volume 39(23), 10 August 2021, p 2528-2534
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors' suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in the Journal of Clinical Oncology, to patients seen in their own clinical practice.
Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape
Short, Nicholas J. MD1,,; Tallman, Martin S. MD2,; Pollyea, Daniel A. MD3,; Ravandi, Farhad MD1,; Kantarjian, Hagop MD1,
doi : 10.1200/JCO.21.00067
Volume 39(23), 10 August 2021, p 2535-2538
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131
Mayer, Ingrid A. MD, MSCI1,,; Zhao, Fengmin PhD2; Arteaga, Carlos L. MD3,; Symmans, William F. MD4,; Park, Ben H. MD, PhD1,; Burnette, Brian L. MD5; Tevaarwerk, Amye J. MD6,; Garcia, Sofia F. PhD7; Smith, Karen L. MD8,; Makower, Della F. MD9; Block, Margaret MD10,; Morley, Kimberly A. MD11; Jani, Chirag R. MD12; Mescher, Craig MD13; Dewani, Shabana J. MD14; Tawfik, Bernard MD15,; Flaum, Lisa E. MD7,; Mayer, Erica L. MD16,; Sikov, William M. MD17,; Rodler, Eve T. MD18; Wagner, Lynne I. PhD19,; DeMichele, Angela M. MD20,; Sparano, Joseph A. MD9,; Wolff, Antonio C. MD8,; Miller, Kathy D. MD21,
doi : 10.1200/JCO.21.00976
Volume 39(23), 10 August 2021, p 2539-2551
Patients with triple-negative breast cancer (TNBC) and residual invasive disease (RD) after completion of neoadjuvant chemotherapy (NAC) have a high-risk for recurrence, which is reduced by adjuvant capecitabine. Preclinical models support the use of platinum agents in the TNBC basal subtype. The EA1131 trial hypothesized that invasive disease-free survival (iDFS) would not be inferior but improved in patients with basal subtype TNBC treated with adjuvant platinum compared with capecitabine.
Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study
Garaventa, Alberto MD1,; Poetschger, Ulrike MSc, PhD2; Valteau-Couanet, Dominique MD3,; Luksch, Roberto MD4; Castel, Victoria MD5; Elliott, Martin MD6,; Ash, Shifra MD7; Chan, Godfrey C. F. MD8,; Laureys, Genevieve MD9; Beck-Popovic, Maja MD10; Vettenranta, Kim MD11; Balwierz, Walentyna MD12,; Schroeder, Henrik MD13; Owens, Cormac MD14,; Cesen, Maja MD15; Papadakis, Vassilios MD16,; Trahair, Toby MD17,; Schleiermacher, Gudrun MD18,; Ambros, Peter MSc, PhD2; Sorrentino, Stefania MD1; Pearson, Andrew D. J. MD19,; Ladenstein, Ruth Lydia MD, PhD20,,
doi : 10.1200/JCO.20.03144
Volume 39(23), 10 August 2021, p 2552-2563
Induction therapy is a critical component of the therapy of high-risk neuroblastoma. We aimed to assess if the Memorial Sloan Kettering Cancer Center (MSKCC) N5 induction regimen (MSKCC-N5) would improve metastatic complete response (mCR) rate and 3-year event-free survival (EFS) compared with rapid COJEC (rCOJEC; cisplatin [C], vincristine [O], carboplatin [J], etoposide [E], and cyclophosphamide [C]).
Risk of Breast Cancer Among Carriers of Pathogenic Variants in Breast Cancer Predisposition Genes Varies by Polygenic Risk Score
Gao, Chi ScD1; Polley, Eric C. PhD2,; Hart, Steven N. PhD2; Huang, Hongyan PhD1; Hu, Chunling MD, PhD2; Gnanaolivu, Rohan MS2; Lilyquist, Jenna PhD2; Boddicker, Nicholas J. PhD2; Na, Jie MS2; Ambrosone, Christine B. PhD3; Auer, Paul L. PhD4; Bernstein, Leslie PhD5; Burnside, Elizabeth S. MD, MPH, MS6; Eliassen, A. Heather ScD1,7; Gaudet, Mia M. PhD8; Haiman, Christopher PhD9; Hunter, David J. ScD1,10; Jacobs, Eric J. PhD8; John, Esther M. PhD11; Lindstrom, Sara PhD12,13; Ma, Huiyan PhD5; Neuhausen, Susan L. PhD5; Newcomb, Polly A. PhD, MPH12,13; O'Brien, Katie M. PhD14; Olson, Janet E. PhD2; Ong, Irene M. PhD6,; Patel, Alpa V. PhD8; Palmer, Julie R. ScD15; Sandler, Dale P. PhD14; Tamimi, Rulla ScD16; Taylor, Jack A. PhD14; Teras, Lauren R. PhD8; Trentham-Dietz, Amy PhD6; Vachon, Celine M. PhD2,; Weinberg, Clarice R. PhD14; Yao, Song PhD3; Weitzel, Jeffrey N. MD5,; Goldgar, David E. PhD17; Domchek, Susan M. MD18,; Nathanson, Katherine L. MD18; Couch, Fergus J. PhD2,; Kraft, Peter PhD1,
doi : 10.1200/JCO.20.01992
Volume 39(23), 10 August 2021, p 2564-2573
This study assessed the joint association of pathogenic variants (PVs) in breast cancer (BC) predisposition genes and polygenic risk scores (PRS) with BC in the general population.
Benefits and Harms of Lung Cancer Screening by Chest Computed Tomography: A Systematic Review and Meta-Analysis
Passiglia, Francesco MD1,; Cinquini, Michela BSc2; Bertolaccini, Luca MD3; Del Re, Marzia MD4,; Facchinetti, Francesco MD5,; Ferrara, Roberto MD6,; Franchina, Tindara MD7,; Larici, Anna R. MD8,; Malapelle, Umberto BSc9,; Menis, Jessica MD10,11,; Passaro, Antonio MD12,; Pilotto, Sara MD13,; Ramella, Sara MD14,; Rossi, Giulio MD15; Trisolini, Rocco MD16,; Novello, Silvia MD, PhD1,,
doi : 10.1200/JCO.20.02574
Volume 39(23), 10 August 2021, p 2574-2585
This meta-analysis aims to combine and analyze randomized clinical trials comparing computed tomography lung screening (CTLS) versus either no screening (NS) or chest x-ray (CXR) in subjects with cigarette smoking history, to provide a precise and reliable estimation of the benefits and harms associated with CTLS.
Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial
Mooney, Kathi PhD, RN1,,; Titchener, Karen MSc1; Haaland, Benjamin MS, PhD1,; Coombs, Lorinda A. PhD, MSN2,; O'Neil, Brock MD1; Nelson, Richard PhD1; McPherson, Jordan P. PharmD, MSc1; Kirchhoff, Anne C. PhD1,; Beck, Anna C. MD1; Ward, John H. MD1,
doi : 10.1200/JCO.20.03609
Volume 39(23), 10 August 2021, p 2586-2593
Patients with cancer experience high rates of morbidity and unplanned health care utilization and may benefit from new models of care. We evaluated an adult oncology hospital at home program's rate of unplanned hospitalizations and health care costs and secondarily, emergency department (ED) use, length of hospital stays, and intensive care unit (ICU) admissions during the 30 days after enrollment.
Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study
Zivanovic, Oliver MD1; Chi, Dennis S. MD1,; Zhou, Qin MS1; Iasonos, Alexia PhD1,; Konner, Jason A. MD1,; Makker, Vicky MD1,; Grisham, Rachel N. MD1,; Brown, Amy K. MD2,; Nerenstone, Stacy MD2; Diaz, John P. MD3,; Schroeder, Eric D. MD3; Langstraat, Carrie L. MD4,; Paroder, Viktoriya MD1; Lakhman, Yulia MD1,; Soldan, Krysten RN1,; Su, Katy MS1; Gardner, Ginger J. MD1,; Andikyan, Vaagn MD1; Guo, Jianxia MD5; Jewell, Elizabeth L. MD1,; Long Roche, Kara MD1; Troso-Sandoval, Tiffany MD1,; Lichtman, Stuart M. MD1,; Moukarzel, Lea A. MD1; Dessources, Kimberly MD1; Abu-Rustum, Nadeem R. MD1,; Aghajanian, Carol MD1,; Tew, William P. MD1; Beumer, Jan MD5,; Sonoda, Yukio MD1,; O'Cearbhaill, Roisin E. MD1,,
doi : 10.1200/JCO.21.00605
Volume 39(23), 10 August 2021, p 2594-2604
The purpose of this phase II study was to evaluate hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin for recurrent ovarian cancer during secondary cytoreductive surgery.
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma
Alig, Stefan MD1; Macaulay, Charles W. MSc, BA1; Kurtz, David M. MD, PhD1,; Duhrsen, Ulrich MD2,; Huttmann, Andreas MD2,; Schmitz, Christine MD2,; Jin, Michael C. BS1; Sworder, Brian J. MD, PhD1,; Garofalo, Andrea BS, BA1; Shahrokh Esfahani, Mohammad PhD1; Nabet, Barzin Y. PhD3,; Soo, Joanne MD1; Scherer, Florian MD1,4; Craig, Alexander F. M. MSc1; Casasnovas, Olivier MD5,; Westin, Jason R. MD6,; Gaidano, Gianluca MD7,; Rossi, Davide MD8,; Roschewski, Mark MD9; Wilson, Wyndham H. MD, PhD9; Meignan, Michel MD10,; Diehn, Maximilian MD, PhD3,11,; Alizadeh, Ash A. MD, PhD1,11,,
doi : 10.1200/JCO.20.02573
Volume 39(23), 10 August 2021, p 2605-2616
Patients with Diffuse Large B-cell Lymphoma (DLBCL) in need of immediate therapy are largely under-represented in clinical trials. The diagnosis-to-treatment interval (DTI) has recently been described as a metric to quantify such patient selection bias, with short DTI being associated with adverse risk factors and inferior outcomes. Here, we characterized the relationships between DTI, circulating tumor DNA (ctDNA), conventional risk factors, and clinical outcomes, with the goal of defining objective disease metrics contributing to selection bias.
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis
Casolino, Raffaella MD1,2; Paiella, Salvatore MD, PhD3; Azzolina, Danila PhD4,5; Beer, Philip A. MD, PhD1,6,; Corbo, Vincenzo PhD7,8; Lorenzoni, Giulia PhD4; Gregori, Dario MD4; Golan, Talia MD, PhD9,; Braconi, Chiara MD, PhD1,10,; Froeling, Fieke E. M. MD, PhD1; Milella, Michele MD, PhD11,; Scarpa, Aldo MD, PhD7,8,; Pea, Antonio MD, PhD3; Malleo, Giuseppe MD, PhD3,; Salvia, Roberto MD, PhD3; Bassi, Claudio MD3; Chang, David K. MD, PhD1,12,; Biankin, Andrew V. MD, PhD1,12,13,,
doi : 10.1200/JCO.20.03238
Volume 39(23), 10 August 2021, p 2617-2631
To analyze the prevalence of homologous recombination deficiency (HRD) in patients with pancreatic ductal adenocarcinoma (PDAC).
How Can We Evaluate the Electronic Patient-Reported Outcome Appropriately?
Shojima, Hikaru MD; Shimomura, Akihiko MD, PhD; Kadowaki, Midori RN, PHN, PhD; Kawamura, Yukino MD; Shimizu, Chikako MD, PhD
doi : 10.1200/JCO.21.00482
Volume 39(23), 10 August 2021, p 2632-2633
Reply to H. Shojima et al
Absolom, Kate PhD; Warrington, Lorraine PhD; Hudson, Eleanor MSc; Hewison, Jenny PhD, MSc; Holch, Patricia PhD; Dawkins, Bryony MSc; Hulme, Claire MA, PhD; Brown, Julia MSc; Velikova, Galina MD, PhD
doi : 10.1200/JCO.21.00684
Volume 39(23), 10 August 2021, p 2633-2634
